Technology
Health
Biotechnology

Oncolytics Biotech

$1.86
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.05 (2.97%) Today
+$0.05 (2.97%) Today

Why Robinhood?

You can buy or sell ONCY and other stocks, options, ETFs, and crypto commission-free!

About

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus called REOLYSIN. Read More The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

Employees
Headquarters
Calgary, Alberta
Founded
1998
Market Cap
31.49M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
62.81K
High Today
$1.90
Low Today
$1.85
Open Price
$1.87
Volume
16.13K
52 Week High
$8.20
52 Week Low
$1.64

Collections

Technology
Health
Biotechnology
Canada
North America

News

Simply Wall StMar 13

How Do Analysts See Oncolytics Biotech Inc. (TSE:ONC) Performing Over The Next Few Years?

Oncolytics Biotech Inc.’s (TSE:ONC) released its most recent earnings update in December 2018, which showed that losses became smaller relative to the prior year’s level – great news for investors Below, I’ve laid out key numbers on how market analysts perceive Oncolytics Biotech’s earnings growth outlook over the next few years and whether the future looks brighter. I will be looking at earnings excluding extraordinary items to exclude one-off activities to get a better understanding of the underlying driv...

52
Seeking AlphaMar 8

Oncolytics Biotech Inc. (ONCY) CEO Matthew Coffey on Q4 2018 Results - Earnings Call Transcript

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2018 Results Earnings Conference Call March 8, 2019 8:30 AM ET Company Participants Michael Moore - VP of IR & Corporate Communications Matthew Coffey - President, CEO Kirk Look - CFO Conference Call Participants Wangzhi Li - Ladenburg Thalmann Operator Good morning. My name is Michelle, and I will be your conference operator today. At this time, I would like to welcome everyone to the Oncolytics Biotech Fourth Quarter Results Conference Call. All lines have ...

31
MarketBeatMar 4

Stock Price, News, & Analysis for Oncolytics Biotech

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck Scho...

0

Earnings

-$0.28
-$0.19
-$0.11
-$0.02
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
-$0.28 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.